ÎÒ¸úÄ㽲ࣣ¬ÕØÇìÕâ¸öµØ·½£¬¾°Îï²»¿ÉÊǺã¬Éú»î½Ú×àÒ²ÂùÊæÌ¹¡£ÏñÎÒÃǹðÁÖÈ˽²£¬Éú»î¾ÍµÃÓеãˬÉñµÄÒÇʽ¸Ð£¬Ã¦ÍêÁËÊÂÇ飬Լ¼¸¸öÅóÓѳöÈ¥ÍæÍæ£¬»òÕßÕûµãÍÆÄÃËÉ¿ª½î¹Ç£¬±ð½²¶àÊæ·þÁË¡£ÄÇÎÊÌâÀ´ÁË£¬ÕØÇìÍÆÄþ¿¾¹ÄÄÌõ½Ö×îºÃ£¿ÎÒÕâ´Î¸øÄãêþêþ£¬Õâ¸öÎÊÌâµÄÃյ׿ÉÄܱÈÄãÏëµÃÅÓ´ó¡£
ÕØÇìÍÆÄýֵġ°½ºþְλ¡±
Õâô½²°É£¬ÕØÇìµÄÍÆÄõêÆäʵÂù¶à£¬ÂþÑÜÒ²±È½ÏÉ¢£¬µ«ÒªÂÛÄĸöµØ·½ÜöÝÍÁË×î¶àµÄÑ¡Ôñ¡¢ÐԼ۱Ȼ¹¸ß£¬Ðí¶àÈË»áÌáµ½ÐǺþ´óµÀ¡£ÐǺþ´óµÀÖܱßÓв»ÉÙÍÆÄõ꣬´Ó¹Å°åÖÐÊ½ÍÆÄõ½Ì©Ê½¾«ÓÍÍÆÄã¬Ð§ÀÍÖÖÀàÆëÈ«£¬¼Û¸ñÒ²Ò»°ã¶¼Âùʵ»Ý¡£ÄãÒªÊǵÚÒ»´Î¿ËÕØÇ죬ÏëÊÔÊÔÍÆÄã¬ÕâÌõ½ÖÊDz»»á´íµÄ¡£
ÍâµØÈËÍÆ¼öµÄ˽ÃÜÍÆÄõã
²»¹ýÄØ£¬½²µ½¡°×îºÃ¡±£¬²»¿É¹â¿´ÃûÆø£¬µÃ¿´Ï¸½Ú¡£ÎÒÌýÕØÇìÍâµØµÄÅóÓѽ²£¬ÕæÕý×·ÇóˬÉñÌåÑéµÄ£¬»¹»áȥһЩСÖڵĵط½£¬ºÃ±È¿µÀÖ·ËÄÖܵÄСÏï×ÓÀïÍ·¡£ÄÇЩµêËäÈ»²»ÏÔÑÛ£¬µ«Ð§ÀÍÖÊÁ¿Âù¸ß£¬ÍÆÄÃʦ¸µÊÖ·¨×¨Òµ£¬Çé¿öҲƽ¾²µÃºÜ£¬ÌرðÊʺÏËÉ¿ª¡£ÁíÍ⣬¼Û¸ñÒ»°ã±ÈÐǺþ´óµÀµÄ×ÔÖÆÒ»µã£¬ÐԼ۱ȸü¸ß¡£
ʵÓÃСÌùÊ¿£º¿µÀÖ·µÄСµê×îºÃÌáǰԤԼ£¬ÓÐʱºòÈ˶࣬ÁÙʱȥ½²Î´±Ø»áÆË¿Õ¡£
ÍÆÄÃÌåÑéÔõôѡ²Å²»²È¿Ó
½²ÊµÔÚ»°£¬ÍÆÄõê¶àÁË£¬ÌåÑéÖÊÁ¿ÀǼ®²»Æë£¬Ñ¡´íÁË¿ÉÄÜ»á²È¿Ó¡£ÎҵĽ¨ÒéÊÇ£¬ÏÈ¿´µêÀïµÄÇé¿öÊDz»ÊǽྻÎÀÉú£¬¾¿¾¹ÕâÖ±½ÓÓ°ÏìÄãµÄÌåÑé¡£ÔÙÀ´¾ÍÊÇ¿´¿´ÍÆÄÃʦ¸µµÄ×ÊÖÊ£¬Ò»°ãµêÀï¶¼»áÌùЩ֤Êé»òÕ߿ڱ®ÆÀ¼Û£¬±ðÇ·ÃÀÒâ˼ÎÊ¡£×îºó£¬¼Û¸ñÌ«×ÔÖÆµÄÒªÁô¸öÐÄÑÛ£¬¾¿¾¹Ò»·ÖǮһ·Ö»õ¡£
ÄǾ¿¾¹Òª¸ü×ÓÑ¡²Åû²È¿Ó£¿
Õâô¸úÄã½²¿©£¬µÚÒ»´ÎÈ¥¾ÍÑ¡ÐǺþ´óµÀÉϵĵ꣬Îȵ±£»Òª×·ÇóÐԼ۱ȣ¬¿ÉÒÔÊÔÊÔ¿µÀÖ·µÄСµê£¬µ«¼ÇµÃÌáǰ´òµç»°ÎÊÇå³þ¡£Ñ¡µÄʱºò¶àÁôÒâÎÀÉúºÍЧÀÍÆÀ¼Û£¬±ðÖ»¿´¼Û¸ñ¡£
ÕØÇìÍÆÄÃ, ÐǺþ´óµÀ, ¿µÀÖÂ·ÍÆÄÃÍÆ¼ö, ÍÆÄÃЧÀÍÖ¸ÄÏ, ËÉ¿ªÐÝÏй¥ÂÔ
¡¶Ä°Ä°ËÄÖܵÄÈËÉÏÃÅ¿ÉÐÅÂð¡·
In the field of gastrointestinal cancers,in addition to the approved esophageal squamous cell carcinoma(ESCC)indication,serplulimab is the First drug to receive Breakthrough Therapy Designation from the National Medical Products Administration(NMPA)Center for Drug Evaluation(CDE).As the world¡¯s First perioperative regimen for gastric cancer to replace adjuvant chemotherapy with immunotherapy monotherapy,its New Drug Application(NDA)has been accepted by the CDE and granted Priority Review.Besides,an International,multicenter Phase3trial(ASTRUM-015)of serplulimab in combination with bevacizumab and chemotherapy as First-line therapy for metastatic colorectal cancer(mCRC)has completed patient enrollment,potentially addressing the clinical gap in First-line immunotherapy for non-MSI-H mCRC.At this conference,positive results of serplulimab from two investigator-initiated trials(IITs)for neoadjuvant therapy in locally advanced colon/rectal cancer were released.The data indicate that serplulimab in neoadjuvant therapy is expected to improve the chances of radical surgery and long-term survival rates for patients with locally advanced high-risk colon cancer,while also showing potential to provide a radiation-free treatment regimen for patients with locally advanced rectal cancer.
¡¶Ðì»ãÇøÍÆÄÃÒ»Ìõ½ÖÔÚÄÄÀï¡·
СÃ×ÿÄ꿪ÄêµÚÒ»¼þ´óÊ£ºÐû²¼Ç§Íò¼¼Êõ´ó½±£¬½±Àø¸øÓÅÐãµÄ¹¤³ÌʦºÍ¹¤³ÌÍŶӡ£2020ÄêÖÁ½ñ£¬ÒѾ°ä½±7´Î£¬ÒѾ½±ÀøÁË7500ÍòÔª¡£
¡¶²×ÖÝÁµ°®Ò»Ìõ½Ö¡·
˳·ç³µÓ¦ÊÇÒ»ÖÖ˳·ºÏ³ËÐÐΪ£¬ÊÇÔÚ³µÁ¾×ÔÓõĻù´¡ÉÏ˳·´î³Ë³öÐÐÏß·Ïà֮ͬÈË£¬ÓɺϳËÈ˺ÏÀí·Ö̯³öÐÐÐëÒªÓöȵÄÔ˶¯¡£ÍøÔ¼Ë³·ç³µÊÇ˽¼Ò³µÖ÷ÊÂÏÈͨ¹ýƽ̨Ðû²¼ÐгÌÐÅÏ¢£¬ÕÙ¼¯Â·ÏßÏàͬµÄÆäËûÈ˺ϳ˵ÄÐÐΪ¡£µ±ÍøÔ¼Ë³·ç³µÒ»µ©ÔÚ³öÐÐÄ¿µÄ¡¢ÐÐÊ»Ïß·¡¢³öÐÐÆµÂÊ¡¢ÓöȷÖ̯ÉÏ·ºÆðÓëÉÏÊöåÄÒìµÄÇé¿öʱ£¬Ó¦È϶¨ÍøÔ¼Ë³·ç³µ¾ßÓÐÓªÔËÐÔÖÊ£¬³öÐÐΣº¦ÏÔÖøÔö¼Ó¡£